Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Italia
    • Utenti registrati
    • 0039 0424-472449 Richiedi informazioni
    • 0039 0424-472449 Richiedi informazioni
    ItalyItaly
      • Part of brands: |
        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        Genomics Precision Diagnostic > Prenatal > Increased Nuchal Translucency Precision Panel

        Increased Nuchal Translucency Precision Panel

        Increased Nuchal Translucency (NT) is defined as an abnormal accumulation of fluid in the nuchal area, which is visualized as a thickened sonolucent area. It is a standardized measure obtained between 11 and 14 weeks of gestation to calculate the risk of a fetus being affected by a chromosomal aneuploidy. 
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Increased Nuchal Translucency (NT) is defined as an abnormal accumulation of fluid in the nuchal area, which is visualized as a thickened sonolucent area. It is a standardized measure obtained between 11 and 14 weeks of gestation to calculate the risk of a fetus being affected by a chromosomal aneuploidy. NT>3.5mm has been found to be associated with fetal chromosomal abnormalities and single-gene disorders as well as cardiac defects and other structural abnormalities in euploid and aneuploid fetuses. Proportionally as NT increases, even with a normal karyotype, there is a higher risk of adverse pregnancy outcomes such as miscarriage, intrauterine death, congenital heart defects and numerous other structural and genetic syndromes. There is not one single cause of increased NT, it is based on a complex and multifactorial process, linked to one or more embryonic processes. It has been shown that a persistently increased NT with a normal karyotype and aCGH has a 4-10% probability of being associated to Noonan Syndrome and/or other RASopathies using Whole Exome Sequencing (WES). However, the general tendency following detection of isolated enlarged NT in an euploid fetus is that most babies with normal detailed ultrasound examination and echocardiography will have uneventful outcomes. 
        • The Igenomix Increased Nuchal Translucency Precision Panel can be used to make a directed and accurate prenatal differential diagnosis of increased nuchal translucency in patients with or without a normal karyotype ultimately leading to a better management and prognosis of the associated comorbidities. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

        Indication

        • The Igenomix Infertility Precision Panel is indicated for those patients with ultrasound measured increased nuchal translucency (TN>3.5mm) with normal or abnormal karyotype and/or aCGH. 

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular confirmation for an accurate clinical diagnosis of associated syndromes of a fetus presenting with increased nuchal translucency.  
        • Reduce burden of parents over prenatally undetectable conditions. 
        • Genetic counselling emphasizing the fact that following detection of isolated enlarged NT, most babies with normal detailed ultrasound examination and echocardiography will have uneventful outcome. 
        • To provide valuable information based on genetic testing combined with fetal ultrasound examination that can influence pregnancy outcome, and provide recurrence risks.  

        Genes & Diseases

        Methodology

        References

        See scientific referrals

        Burger, N. B., Bekker, M. N., de Groot, C. J., Christoffels, V. M., & Haak, M. C. (2015). Why increased nuchal translucency is associated with congenital heart disease: a systematic review on genetic mechanisms. Prenatal diagnosis, 35(6), 517–528. https://doi.org/10.1002/pd.4586 

        Matyášová, M., Dobšáková, Z., Hiemerová, M., Kadlecová, J., Nikulenkov Grochová, D., Popelínská, E., Svobodová, E., & Vlašín, P. (2019). Prenatal diagnosis of Noonan syndrome in fetuses with increased nuchal translucency and a normal karyotype. Prenatální diagnostika syndromu Noonanové u plodů se zvýšeným šíjovým projasněním a normálním karyotypem. Ceska gynekologie, 84(3), 195–200. 

        Sinajon, P., Chitayat, D., Roifman, M., Wasim, S., Carmona, S., Ryan, G., Noor, A., Kolomietz, E., & Chong, K. (2020). Microarray and RASopathy-disorder testing in fetuses with increased nuchal translucency. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 55(3), 383–390. https://doi.org/10.1002/uog.20352 

        Alamillo, C. M., Fiddler, M., & Pergament, E. (2012). Increased nuchal translucency in the presence of normal chromosomes. Current Opinion in Obstetrics & Gynecology, 24(2), 102-108. doi:10.1097/gco.0b013e3283505b25 

        Bilardo, C., Timmerman, E., Pajkrt, E., & Van Maarle, M. (2010). Increased nuchal translucency in euploid fetuses-what should we be telling the parents? Prenatal Diagnosis, 30(2), 93-102. doi:10.1002/pd.2396 

        descargar

        Detail description

        Download

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        GUIDA

        Fertilità
        Prevenzione di malattie ereditarie
        Gravidanza serena

        I NOSTRI SERVIZI

        Soluzioni genetiche
        Informazioni sulla genetica

        PANORAMICA

        Informazioni su Igenomix
        Contatti
        Come inviare un campione
        Qualità
        Lavora con noi
        News and Press

           0039 0424-472449
        Contatti
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        Linguaggio

        [2019] © Igenomix Politica sulla privacyPolitica qualità Politica dei cookie       Soddisfazione       Manuale dell’utente

        Richiedi informazioni








        • reCAPTCHA demo: Simple page











        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        • Italia
        • Utenti registrati
        • Area pazienti
        • Area cliniche

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        Italy
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.